Next Article in Journal
Performance of Modified Early Warning Score (MEWS) for Predicting In-Hospital Mortality in Traumatic Brain Injury Patients
Previous Article in Journal
Cervical Human Papillomavirus Infection (HPV) and High Oncogenic Risk Genotypes among Women Living with HIV in Asia: A Meta-Analysis

Diagnostic Performance of the Fujifilm SILVAMP TB-LAM in Children with Presumptive Tuberculosis

Institut d’Investigació Germans Trias i Pujol, CIBER Enfermedades Respiratorias, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain
Department of Pediatrics, Division of Tuberculosis, Hôpital Saint-Damien, Nos Petits-Frères et Sœurs, Port-au-Prince 6112, Haiti
Department of Radiology and Imaging Diagnose, Centre d’Atenció Primària (CAP) Manso, 08015 Barcelona, Spain
Servei de Pediatria, Atenció Primària, Unitat de Investigació Fundació Mútua Terrassa, Hospital Universitari Mútua Terrassa, 08221 Barcelona, Spain
Stop TB Partnership, TB Reach, 1218 Geneva, Switzerland
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
Author to whom correspondence should be addressed.
Senior co-authors.
Academic Editor: Luis Garcia-Marcos
J. Clin. Med. 2021, 10(9), 1914;
Received: 24 March 2021 / Revised: 17 April 2021 / Accepted: 23 April 2021 / Published: 28 April 2021
(This article belongs to the Section Infectious Diseases)
Current diagnostics for tuberculosis (TB) only manage to confirm a small proportion of children with TB and require respiratory samples, which are difficult to obtain. There is a need for non-invasive biomarker-based tests as an alternative to sputum testing. Fujifilm SILVAMP TB lipoarabinomannan (FujiLAM), a lateral-flow test to detect lipoarabinomannan in urine, is a novel non-sputum-based point-of-care diagnostic reported to have increased sensitivity for the diagnosis of TB among human immunodeficiency virus (HIV)-infected adults. We evaluate the performance of FujiLAM in children with presumptive TB. Fifty-nine children attending a paediatric hospital in Haiti with compatible signs and symptoms of TB were examined using Xpert MTB/RIF, smear microscopy and X-rays, and classified according to the certainty of diagnosis into bacteriologically confirmed TB (n = 5), unconfirmed TB (bacteriologically negative, n = 50) and unlikely TB (n = 4). Healthy children (n = 20) were enrolled as controls. FujiLAM sensitivity and specificity were 60% and 95% among children with confirmed TB. FujiLAM’s high specificity and its characteristics as a point-of-care indicate the test has a good potential for the diagnosis of TB in children. View Full-Text
Keywords: tuberculosis; diagnosis; lipoarabinomannan; LAM; children; urine; point-of-care tuberculosis; diagnosis; lipoarabinomannan; LAM; children; urine; point-of-care
MDPI and ACS Style

Comella-del-Barrio, P.; Molina-Moya, B.; Gautier, J.; Villar-Hernández, R.; Doresca, M.J.C.; Sallés-Mingels, B.; Canales-Aliaga, L.; Narcisse, M.; Pérez-Porcuna, T.M.; Creswell, J.; Cuevas, L.E.; Domínguez, J. Diagnostic Performance of the Fujifilm SILVAMP TB-LAM in Children with Presumptive Tuberculosis. J. Clin. Med. 2021, 10, 1914.

AMA Style

Comella-del-Barrio P, Molina-Moya B, Gautier J, Villar-Hernández R, Doresca MJC, Sallés-Mingels B, Canales-Aliaga L, Narcisse M, Pérez-Porcuna TM, Creswell J, Cuevas LE, Domínguez J. Diagnostic Performance of the Fujifilm SILVAMP TB-LAM in Children with Presumptive Tuberculosis. Journal of Clinical Medicine. 2021; 10(9):1914.

Chicago/Turabian Style

Comella-del-Barrio, Patricia, Bárbara Molina-Moya, Jacqueline Gautier, Raquel Villar-Hernández, Mariette Jean Coute Doresca, Beatriz Sallés-Mingels, Lydia Canales-Aliaga, Margareth Narcisse, Tomás M. Pérez-Porcuna, Jacob Creswell, Luis E. Cuevas, and José Domínguez. 2021. "Diagnostic Performance of the Fujifilm SILVAMP TB-LAM in Children with Presumptive Tuberculosis" Journal of Clinical Medicine 10, no. 9: 1914.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop